NBP Earnings Date: Nov 12, 2026 (Estimated) — NovaBridge Biosciences
NASDAQ · Healthcare · Biotechnology
Updated
When is NBP's next earnings date?
NovaBridge Biosciences (NBP) is expected to report earnings on Thursday, November 12, 2026; the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.08 on revenue of $33.6M.
How did NBP do in its last earnings report?
In its most recent report on Aug 20, 2026 (H1 2026), NovaBridge Biosciences posted EPS of -$0.33 versus the -$0.03 estimate, a miss of 135.7%. Revenue was $0. The stock's 1-day post-earnings move was -3.5%.
How much does NBP stock move after earnings?
NBP beat EPS estimates in 2 of its last 7 reported quarters. Over the last 3 reports the stock moved an average of 3.7% (up or down) in the day after earnings.
About NovaBridge Biosciences
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-20 | H1 2026 | -0.03 | -0.33 | -135.71% | $0 | ❌ Miss | -3.54% | -5.56% | -19.19% |
| 2026-07-29 | -0.01 | -0.22 | — | — | ❌ Miss | -6.29% | -5.71% | +6.86% | |
| 2026-04-07 | FY 2025 | -0.22 | -0.21 | +4.55% | $0 | ✅ Beat | -1.21% | +2.42% | -9.27% |
| 2022-08-30 | -1.11 | -0.83 | — | $7.7M | ✅ Beat | — | — | — | |
| 2022-03-29 | -0.34 | -1.17 | — | $11.0M | ❌ Miss | — | — | — | |
| 2021-11-12 | — | -1.24 | — | $5.4M | — | — | — | — | |
| 2021-08-31 | -0.36 | -0.99 | — | $2.8M | ❌ Miss | — | — | — | |
| 2021-03-29 | 0.91 | 0.85 | — | $238.6M | ❌ Miss | — | — | — |
Showing last 8 quarters.